Tim Andrews and Massachusetts General Hospital bought a risky bridge

By Klaus Berger · Reporting from Frankfurt · September 4, 2026

There is a stark arithmetic to human failure that no amount of rhetoric can obscure.

The 271-Day Balance Sheet of Desperation and Science

There is a stark arithmetic to human failure that no amount of rhetoric can obscure. As the BBC and El País have reported, more than 100,000 patients languish on waiting lists for a kidney in the United States, while a mere 25,000 transplants occur annually. In the European Union, the ledger reads 53,343 souls waiting in structural limbo. Into this cruel mathematical deficit stepped Tim Andrews, a 66-year-old former stock car racing driver and engineer who, facing a seven-year waitlist and an average life expectancy on dialysis of just five years, received a genetically modified pig kidney at Massachusetts General Hospital. For 271 days, that porcine organ functioned inside him. As Yonhap and ABC Color note, this case marks a "First successful organ transplant" crossing the boundary of xenogenic material into a human body. But do not mistake this technological marvel for a systemic solution. It is a brilliant, costly patch on a leaking hull.

Sixty-Nine Edits Cannot Outrun the Rulebook of Risk

Let us look past the miraculous headlines and examine the balance sheet of eGenesis and its Yucatan miniature pigs. To achieve 271 days of function, scientists engineered 69 genomic modifications, removing major carbohydrate antigens and disabling retroviruses. Yet, as Dr. Leonardo Riella and his team documented in The Lancet, the biological bill eventually came due: an early T-cell rejection, a subsequent bout of infectious complications requiring reduced immunosuppression, and finally, thrombotic microangiopathy that forced the organ’s removal. Andrews survived on dialysis for another 82 days before receiving a human donor kidney. The strongest opposing case for xenotransplantation is compelling: when the alternative is death on a dialysis machine, any functioning biological filter is a triumph. But this confuses a bridge with a destination. Moral hazard thrives when we treat extraordinary biomedical interventions as substitutes for rational, sustainable organ procurement policies. A currency union cannot survive without fiscal discipline, and a healthcare system cannot survive by relying on transgenic livestock to mask a chronic shortage of altruism.

The Bridge Is Not the Territory

We must be precise about what this milestone represents. Transplants are defined by biology as procedures where material is moved to replace a damaged function, forcing the body to confront immunological rejection. Whether the graft comes from a cadaver or a genetically altered animal, the fundamental rulebook of immunology remains unamended by venture capital or corporate optimism. Xenotransplantation will undoubtedly be deployed by major academic medical centers as a standard bridge therapy, as Dr. Riella envisions, allowing critical patients to bypass years of dialysis. Firms like eGenesis will see accelerated regulatory scrutiny and investment rounds as they refine these 69 genetic edits to mitigate microvascular failures. But a bridge is meant to carry you to the other side, not trap you in a perpetual state of experimental maintenance.

When the market in human organs fails to clear through voluntary donation, introducing transgenic substitutes is not a cure for our systemic inertia; it is an expensive deferral of the reckoning. We are applauding the ingenuity of the mechanic while ignoring the structural rot of the vehicle. Stability is a policy, not an accident, and until we fix the allocation and procurement of human organs, we are merely mortgaging human desperation to biotech balance sheets.

Tim Andrews and Massachusetts General Hospital bought a risky bridge

The 271-Day Balance Sheet of Desperation and Science

Sixty-Nine Edits Cannot Outrun the Rulebook of Risk

The Bridge Is Not the Territory

Sources